[go: up one dir, main page]

CY1119394T1 - Ορθορομβικη κρυσταλλικη ingenol mebutate - Google Patents

Ορθορομβικη κρυσταλλικη ingenol mebutate

Info

Publication number
CY1119394T1
CY1119394T1 CY20171100767T CY171100767T CY1119394T1 CY 1119394 T1 CY1119394 T1 CY 1119394T1 CY 20171100767 T CY20171100767 T CY 20171100767T CY 171100767 T CY171100767 T CY 171100767T CY 1119394 T1 CY1119394 T1 CY 1119394T1
Authority
CY
Cyprus
Prior art keywords
ingenol mebutate
xrc
crystalline form
relates
crystal
Prior art date
Application number
CY20171100767T
Other languages
English (en)
Inventor
Steven Martin Ogbourne
Original Assignee
Leo Pharma A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44318125&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1119394(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Leo Pharma A/S filed Critical Leo Pharma A/S
Publication of CY1119394T1 publication Critical patent/CY1119394T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
    • C07C69/533—Monocarboxylic acid esters having only one carbon-to-carbon double bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/48—Separation; Purification; Stabilisation; Use of additives
    • C07C67/52—Separation; Purification; Stabilisation; Use of additives by change in the physical state, e.g. crystallisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/86—Ring systems containing bridged rings containing four rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Liquid Crystal Substances (AREA)

Abstract

Η παρούσα εφεύρεση αφορά μια νέα κρυσταλλική μορφή ingenol mebutate, τις μεθόδους παρασκευής της και τη χρήση της. Πιο συγκεκριμένα, η εφεύρεση σχετίζεται με τη μετατροπή της άμορφης ingenol mebutate (ιντενολ-3-αλογονιδίου, ΡΕΡ005) σε κρυσταλλική μορφή, η οποία χαρακτηρίζεται από κρυσταλλογραφία ακτινών Χ απλού κρυστάλλου (XRC), φάσμα Φασματοσκοπίας Υπέρυθρου Μετασχηματισμού Fourier - Αποσβένουσας Ολικής Ανάκλασης (FTIR-ATR) και διαφορική θερμιδομετρία σάρωσης (DSC).
CY20171100767T 2010-04-16 2017-07-18 Ορθορομβικη κρυσταλλικη ingenol mebutate CY1119394T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32503210P 2010-04-16 2010-04-16
PCT/IB2011/001277 WO2011128780A1 (en) 2010-04-16 2011-04-18 Crystalline ingenol mebutate

Publications (1)

Publication Number Publication Date
CY1119394T1 true CY1119394T1 (el) 2018-02-14

Family

ID=44318125

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171100767T CY1119394T1 (el) 2010-04-16 2017-07-18 Ορθορομβικη κρυσταλλικη ingenol mebutate

Country Status (25)

Country Link
US (2) US8653133B2 (el)
EP (1) EP2558435B1 (el)
JP (1) JP2013525300A (el)
KR (1) KR20130091647A (el)
CN (1) CN102844294A (el)
AU (1) AU2011241893B2 (el)
BR (1) BR112012026420A2 (el)
CA (1) CA2796044A1 (el)
CY (1) CY1119394T1 (el)
DK (1) DK2558435T3 (el)
ES (1) ES2633814T3 (el)
HR (1) HRP20171072T1 (el)
HU (1) HUE034138T2 (el)
IL (1) IL222265A (el)
LT (1) LT2558435T (el)
MX (1) MX338480B (el)
NZ (1) NZ603567A (el)
PL (1) PL2558435T3 (el)
PT (1) PT2558435T (el)
RS (1) RS56337B1 (el)
RU (1) RU2572618C2 (el)
SI (1) SI2558435T1 (el)
SM (1) SMT201700350T1 (el)
WO (1) WO2011128780A1 (el)
ZA (1) ZA201207409B (el)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10143638B2 (en) * 2009-02-13 2018-12-04 Leo Laboratories Limited Method of treating skin with ingenol mebutate
MX338480B (es) 2010-04-16 2016-04-19 Leo Pharma As Ingenol mebutato cristalino.
EP3640236A1 (en) * 2010-07-20 2020-04-22 Leo Laboratories Limited A method of producing ingenol-3-angelate
US9402823B2 (en) 2010-12-17 2016-08-02 Leo Laboratories Limited Ingenols for treating seborrheic keratosis
WO2012176015A1 (en) * 2011-06-24 2012-12-27 Leo Pharma A/S Methods for treating uv-damaged skin and scc tumors and for removing tattoos with topical ingenol mebutate
AU2012364664B2 (en) * 2011-12-12 2015-10-08 Leo Laboratories Limited Gel compositions
US20140350101A1 (en) * 2011-12-12 2014-11-27 Leo Laboratories Limited Gel compositions
US20140343141A1 (en) * 2011-12-12 2014-11-20 Leo Laboratories Limited Topical composition comprising an ingenol derivative and a surfactant-cosolvent mixture
EP2806869A1 (en) * 2012-01-26 2014-12-03 Leo Pharma A/S Ingenol mebutate in combination with cryotherapy for the treatment of actinic keratosis
US20130251782A1 (en) * 2012-03-22 2013-09-26 Leo Laboratories Limited Topical application of ingenol mebutate with occlusion
EP2858629A1 (en) * 2012-06-08 2015-04-15 Leo Laboratories Limited A topical gel composition comprising an ingenol derivative and a solvent mixture
WO2014090859A1 (en) * 2012-12-12 2014-06-19 Leo Laboratories Limited Gel compositions
GB201222403D0 (en) * 2012-12-12 2013-01-23 Leo Lab Ltd Gel compositions
GB201222406D0 (en) * 2012-12-12 2013-01-23 Leo Lab Ltd Gel compositions
GB201222405D0 (en) * 2012-12-12 2013-01-23 Leo Lab Ltd Gel compositions
AU2014100280B4 (en) * 2014-03-24 2015-01-15 Leo Pharma A/S A method of treating skin lesions
US9526714B2 (en) * 2014-03-24 2016-12-27 Leo Laboratories Limited Method for treating skin lesions with ingenol mebutate
CN107510651A (zh) * 2016-06-17 2017-12-26 王成 一种小分子免疫药物的纳米靶向制剂制备及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO864097A0 (en) 1997-08-19 1997-09-11 Peplin Pty Ltd Anti-cancer compounds
EP1773389A4 (en) * 2004-05-07 2008-09-10 Massachusetts Inst Technology METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER RELATING TO THE RECOGNITION OF THE BACH1 PHOSPHORYLE BRCA1 BRCT DOMAIN
RU2438689C9 (ru) * 2005-06-28 2012-03-10 Амазония Фитомедикаментус ЛТДА Активная фракция экстракта млечного сока растения семейства euphorbiaceae, способ ее получения, композиция на ее основе (варианты) и способ лечения заболеваний, связанных с пролиферацией клеток (варианты)
CA2629337A1 (en) 2005-11-14 2007-05-18 Peplin Research Pty Ltd Use of angeloyl-substituted ingenanes in combination with other agents to treat cancer
CN101360506A (zh) * 2005-11-25 2009-02-04 派普林研究股份有限公司 创伤愈合的方法
GB0525680D0 (en) 2005-12-16 2006-01-25 Peplin Ltd Therapeutic compositions
KR101485883B1 (ko) * 2007-04-30 2015-01-27 레오 라보라토리즈 리미티드 바이러스 유도 병변의 치료
MX338480B (es) 2010-04-16 2016-04-19 Leo Pharma As Ingenol mebutato cristalino.

Also Published As

Publication number Publication date
RU2572618C2 (ru) 2016-01-20
WO2011128780A1 (en) 2011-10-20
RS56337B1 (sr) 2017-12-29
EP2558435B1 (en) 2017-06-07
JP2013525300A (ja) 2013-06-20
US8653133B2 (en) 2014-02-18
ES2633814T3 (es) 2017-09-25
LT2558435T (lt) 2017-07-25
PT2558435T (pt) 2017-07-24
US20110257262A1 (en) 2011-10-20
US9440906B2 (en) 2016-09-13
SI2558435T1 (sl) 2017-10-30
ZA201207409B (en) 2014-06-25
AU2011241893B2 (en) 2014-11-06
SMT201700350T1 (it) 2017-09-07
AU2011241893A1 (en) 2012-12-06
IL222265A (en) 2015-04-30
NZ603567A (en) 2013-10-25
DK2558435T3 (en) 2017-08-14
KR20130091647A (ko) 2013-08-19
CA2796044A1 (en) 2011-10-20
MX338480B (es) 2016-04-19
EP2558435A1 (en) 2013-02-20
MX2012011844A (es) 2012-11-30
CN102844294A (zh) 2012-12-26
PL2558435T3 (pl) 2017-10-31
BR112012026420A2 (pt) 2016-08-02
HRP20171072T1 (hr) 2017-10-06
HUE034138T2 (en) 2018-01-29
US20150025265A1 (en) 2015-01-22
IL222265A0 (en) 2012-12-31
RU2012148720A (ru) 2014-05-27

Similar Documents

Publication Publication Date Title
CY1119394T1 (el) Ορθορομβικη κρυσταλλικη ingenol mebutate
CY1123145T1 (el) Anti-cd40 αντισωματα
CY1122350T1 (el) Μεθοδος παρασκευης ινγενολ-3-αγγελικου
CR20130071A (es) Anticuerpos para el receptor del factor de crecimiento epidérmico 3 (her 3)
CY1119843T1 (el) Φαινυλοξικη l-ορνιθινη και μεθοδοι παρασκευης αυτης
HUE036085T2 (hu) Nagy tisztaságú és kristályos dimetil-fumarát elõállítására szolgáló eljárás
MX2013015393A (es) Inmunocitosinas basadas en un dominio sushi de il-15 y de il-15ra.
MX355428B (es) Formas cristalinas del acido [ (4-hidroxi-1-metil-7-fenoxi-isoquin olin-3-carbonil) -amino] -acetico inhibidor de prolil hidroxilasa.
IL221760A (en) Human monoclonal antibodies derived from human b cells and having neutralizing activity against influenza a viruses
EP2785850A4 (en) METHOD FOR CONVERTING BIOMASS INTO AN OXYGENIZED ORGANIC COMPOUND, DEVICE THEREFOR AND COMPOSITIONS MADE IN THIS METHOD
EP2599902A4 (en) STEAM PHASE CULTIVATED CARBON FIBER AGGREGATE
CY1118439T1 (el) Νεοι συγκρυσταλλοι αγομελατινης
EA201390613A1 (ru) Обогащенный дейтерием расагилин
JP2014518898A5 (el)
FR2960354B1 (fr) Dispositif de production de très hautes fréquences par battement de fréquences lumineuses.
EP2588682A4 (en) SAVED ROOFTOP NETWORK WITH A FUEL
CY1119147T1 (el) Νεο αλας toy abexinostat, συναφης κρυσταλλικη μορφη, μεθοδος παρασκευης τους και οι φαρμακευτικες συνθεσεις που τις περιεχουν
CY1119625T1 (el) Νεα κρυσταλλικη μορφη vii της αγομελατινης, μεθοδος παρασκευης και χρηση της και φαρμακευτικη συνθεση που την περιεχει
CY1123265T1 (el) Μια αναλυση κυτταρικως μεσολαβουμενης ανοσοαποκρισhς
CY1119492T1 (el) Παραγωγα καρβαμικα/ουριας
PE20150186A1 (es) Catalizadores
CY1123193T1 (el) Εστερας α-ασαρυλ-αλδεϋδης, μεθοδος παρασκευης αυτου και εφαρμογη αυτης
CY1119748T1 (el) Υποκατασταθεντα 2-αλκυλ-1-οξο-ν-φαινυλ-3-ετεροαρυλ-1,2,3,4-τετραϋδροϊσοκινολιν-4-καρβοξαμιδια για ανθελονοσιακες θεραπειες
NZ720340A (en) Synthesis of trans-8-chloro-5-methyl-1 -[4-(pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4h-2,3,5,10b-tetraaza-benzo[e]azulene and crystalline forms thereof
JP2012250569A5 (el)